

## Anti-Integrin alpha 4 [Natalizumab] Standard Size Ab00716-13.0

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

**Isotype and Format:** Human IgG4, Kappa

**Clone Number:** Natalizumab

**Alternative Name(s) of Target:** CD49D; alpha 4 subunit of VLA-4 receptor; ITGA4; Integrin alpha-IV

**UniProt Accession Number of Target Protein:** P13612

**Published Application(s):** Block, FC

**Published Species Reactivity:** Human

**Immunogen:** The RAMOS cell line, a non-EBV releasing cell line, injected into mice.

**Specificity:** This antibody binds to the alpha 4 binds subunit of  $\alpha 4\beta 1$  (also known as very late antigen 4 [VLA-4] or CD49d-CD29) and  $\alpha 4\beta 7$  integrin

**Application Notes:** This antibody binds to human integrin alpha 4 and has been used to treat Multiple Sclerosis and Crohn's Disease.

**Antibody First Published in:** Sheremata et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS Neurology. 1999 Mar 23;52(5):1072-4. [PMID:10102433](#)

**Note on publication:** Describes the safety and pharmacokinetic characterization of this antibody in a clinical setting.

### Product Form

**Size:** 200 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.